|Bid||333.56 x 800|
|Ask||333.69 x 900|
|Day's Range||330.83 - 335.93|
|52 Week Range||249.17 - 388.67|
|Beta (3Y Monthly)||1.74|
|PE Ratio (TTM)||15.49|
|Earnings Date||Apr 22, 2019 - Apr 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||385.63|
The decline was triggered by a Patent Trial and Appeal Board (PTAB) decision late Wednesday to consider Mylan NV’s challenge to a Biogen patent covering Biogen’s multiple sclerosis drug. The patent is critical in extending the medicine’s exclusivity into the next decade, and the PTAB’s ruling raises concerns about Tecfidera estimates, UBS analyst Carter Gould wrote in a note.
Mylan filled an inter partes review for Biogen's “514 patent,” the drug maker’s treatment patent on Tecfidera. The IPR was instituted on Wednesday.
Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).
Want to help shape the future of investing tools? Participate in a short research study and receive a subscription valued at $60. Knowing which valuation model to use for financial Read More...
Big biotech stocks are having a bad day Wednesday, following muted guidance from (AMGN) (AMGN) and downbeat news about potential Alzheimer’s treatments from a rival of (BIIB) (BIIB). It’s a downbeat day for Amgen and Biogen, although that hasn’t hurt their smaller peers much. Amgen took a hit after reporting fourth-quarter earnings.
Investing.com - Biogen Inc (NASDAQ:BIIB) reported fourth quarter earnings that beat analysts' expectations on Tuesday and revenue that topped forecasts.
Biotech stocks are on a roll so far this year. With Amgen, Biogen, and Celgene all set to report earnings this week, here's what Baird biotech analyst Brian Skorney says investors should be watching.
Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.
While sales of Biogen's (BIIB) MS franchise are expected to be stable in the fourth quarter that of Spinraza are likely to increase.